| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 北京双鹭药业股份有限公司是一家主要从事基因工程药物的研究开发、生产和经营,研究开发并投放市场具有自主知识产权的2个国家一类新药和8个国家二类新药的公司.一些研究开发项目,曾多次获得北京市及国家科技进步一、二等奖,是4项国家"863"计划成果的产业化基地.2010年公司还申请5项专利,1项专利获得授权,并入选2010年国家火炬计划重点高新技术企业、中关村科技园海淀园首批"百家创新企业"、"北京生物医药产业跨越发展工程"(G20工程)和中关村国家自主创新示范区首批"十百千工程"重点培育企业。 | ||||||||||||||||||||||||
| Main Business | 主要专注于基因工程及相关药物的研究开发和生产经营，紧紧围绕疾病谱的变化布局研发、生产和服务领域。 | ||||||||||||||||||||||||
| Legal Representative | 徐明波 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 梁淑洁 | ||||||||||||||||||||||||
| Solicitors | 北京市君泽君律师事务所 | ||||||||||||||||||||||||
| Auditors | 中洲光华会计师事务所有限公司 | ||||||||||||||||||||||||
| Tel No | 010-88627635 | ||||||||||||||||||||||||
| Fax No | 010-88795883 | ||||||||||||||||||||||||
| Website | www.slpharm.com.cn | ||||||||||||||||||||||||
| slpharm@slpharm.com.cn;lsj@slpharm.com.cn ;wenyang@slpharm.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 09/09/2004 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.070 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.020 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.424 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.578B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |